MedTrace Logo

Diagnostics of Clinical Hyperandrogenism

NCT06530498 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1330

Last updated 2026-04-02

No results posted yet for this study

Summary

The optimal cut-off value for diagnosing hirsutism in the modified Ferriman-Gallwey (mFG) point scale in the Polish population is not known. The correlation of mFG with the severity of androgenetic alopecia in the Ludwig scale (LS) is not known.

The aim of the study is to determine the cut-off point for the diagnosis of hirsutism and to assess the correlation of the mFG scale score with the LS of androgenetic alopecia severity.

Conditions

  • Anovulation
  • PCOS

Interventions

DIAGNOSTIC_TEST

Assessment of the severity of hirsutism using the visual modified Ferriman-Gallwey scale

Assessment of the severity of hirsutism using the visual modified Ferriman-Gallwey scale in 9 body regions rated from 0 (no growth of terminal hair) to 4 (extensive hair growth), thus with a score ranging from 0 (the lowest score - no hirsutism) to 36 points (the highest score - the greatest severity of hirsutism)

DIAGNOSTIC_TEST

Assessment of the severity of endogenetic alopecia using the visual Ludwig Scale

Visual assessment of baldness on the Ludwig scale from I (least severe baldness) to III (most severe baldness): Type I - minimal thinning of the mid-line parting in the hair; Type II - gradual thinning and noticeable widening of the mid-line parting in the hair; Type III - Heavy to total thinning of the mid-line

Sponsors & Collaborators

  • Jagiellonian University

    lead OTHER

Principal Investigators

  • Kazimierz Pityński, Prof. · Jagiellonian University

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-02-29
Primary Completion
2025-06-30
Completion
2025-10-30

Countries

  • Poland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06530498 on ClinicalTrials.gov